JCO Precis Oncol. 2025 Oct;9:e2500557. doi: 10.1200/PO-25-00557. Epub 2025 Oct 30.
ABSTRACT
PURPOSE: CNS tumors are a significant cause of death in the adolescent and young adult (AYA; age 15-39 years) population; however, these patients often lack standardized treatments.
METHODS: In Canada, we have established national multidisciplinary virtual AYA CNS tumor board rounds (national rounds) to improve and standardize care. From November 2021 to June 2024, 185 AYA patients with CNS tumors were presented from centers nationwide, including 138 patients with glioma.
RESULTS: Before case presentation, 5.1% of patients with glioma were taking targeted agents or were enrolled in clinical trials. However, after national rounds, 72.6% of patients with pediatric-type glioma and 45.9% of patients with adult-type glioma were recommended clinical trials and/or targeted agents. Among the 44 patients with glioma who had received radiation therapy before national rounds, only 14 were recommended further radiation. Cumulatively, 68.9% of patients analyzed received a treatment recommendation that represented a change in clinical management compared with their previous treatments. Concurrently, we performed molecular review of 174 AYA CNS tumors during the study time frame. Using TruSight, we identified gene fusions involving BRAF and FGFR1 in 17.9% and 7.4% of patients with low-grade glioma, respectively. Moreover, single-nucleotide variants in BRAF and FGFR1 were detected in 7.4% and 12.6% of patients with low-grade glioma, respectively.
CONCLUSION: Our results suggest that national rounds with centralized molecular review can direct AYA patients with CNS tumors toward targeted agents and clinical trials, while deferring radiation therapy. Taken together, our work details an ongoing effort to improve and standardize care of AYA patients with CNS tumors in Canada.
PMID:41166677 | DOI:10.1200/PO-25-00557
